Standout Papers

Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signalin... 2009 2026 2014 2020 2.5k
  1. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling (2009)
    Stuart M. Chambers, Christopher A. Fasano et al. Nature Biotechnology
  2. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (2018)
    Jae H. Park, Isabelle Rivière et al. New England Journal of Medicine
  3. Chimeric Antigen Receptor Therapy (2018)
    Carl H. June, Michel Sadelain New England Journal of Medicine
  4. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection (2017)
    Justin Eyquem, Jorge Mansilla‐Soto et al. Nature
  5. The Basic Principles of Chimeric Antigen Receptor Design (2013)
    Michel Sadelain, Renier J. Brentjens et al. Cancer Discovery
  6. Gene therapy comes of age (2018)
    Cynthia E. Dunbar, Katherine A. High et al. Science
  7. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade (2018)
    Theodoros Giavridis, Sjoukje J. C. van der Stegen et al. Nature Medicine
  8. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition (2016)
    Leonid Cherkassky, Aurore Morello et al. Journal of Clinical Investigation
  9. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor (2002)
    John Maher, Renier J. Brentjens et al. Nature Biotechnology
  10. Involvement of Granulocyte-Macrophage Colony-Stimulating Factor in Pulmonary Homeostasis (1994)
    Glenn Dranoff, Alexander D. Crawford et al. Science
  11. Senolytic CAR T cells reverse senescence-associated pathologies (2020)
    Corina Amor, Judith Feucht et al. Nature
  12. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells (2012)
    Christopher C. Kloss, Maud Condomines et al. Nature Biotechnology
  13. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs (2009)
    Gabsang Lee, Eirini P. Papapetrou et al. Nature
  14. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells (2015)
    Zeguo Zhao, Maud Condomines et al. Cancer Cell
  15. Therapeutic T cell engineering (2017)
    Michel Sadelain, Isabelle Rivière et al. Nature
  16. PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses (2013)
    V D Fedorov, Maria Themeli et al. Science Translational Medicine
  17. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy (2021)
    Emma Morris, Sattva S. Neelapu et al. Nature reviews. Immunology
  18. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning (2012)
    Hollie J. Pegram, James Lee et al. Blood
  19. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 (2003)
    Renier J. Brentjens, Jean‐Baptiste Latouche et al. Nature Medicine
  20. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape (2019)
    Mohamad Hamieh, Anton Dobrin et al. Nature
  21. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity (2014)
    Prasad S. Adusumilli, Leonid Cherkassky et al. Science Translational Medicine
  22. The pharmacology of second-generation chimeric antigen receptors (2015)
    Sjoukje J. C. van der Stegen, Mohamad Hamieh et al. Nature Reviews Drug Discovery
  23. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells (2019)
    Katrin Mestermann, Theodoros Giavridis et al. Science Translational Medicine
  24. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors (2015)
    Aurore Morello, Michel Sadelain et al. Cancer Discovery
  25. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency (2018)
    Judith Feucht, Jie Sun et al. Nature Medicine
  26. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction (2024)
    Corina Amor, Yu-Jui Ho et al. Nature Aging

Immediate Impact

12 by Nobel laureates 40 from Science/Nature 136 standout
Sub-graph 1 of 15

Citing Papers

Co-opting signalling molecules enables logic-gated control of CAR T cells
2023 StandoutNature
CAR T therapy beyond cancer: the evolution of a living drug
2023 StandoutNature
245 intermediate papers

Works of Michel Sadelain being referenced

Senolytic CAR T cells reverse senescence-associated pathologies
2020 StandoutNature
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
2013
and 95 more

Author Peers

Author Last Decade Papers Cites
Michel Sadelain 22300 15816 10770 355 37.1k
Bruce L. Levine 22282 9047 13718 253 31.9k
Malcolm K. Brenner 23530 9017 12811 487 35.0k
Stephan A. Grupp 20863 7996 8804 322 28.5k
Gianpietro Dotti 18657 7479 10206 284 25.6k
Cliona M. Rooney 24123 6249 12419 384 30.8k
Nicholas P. Restifo 38419 17403 45370 346 63.8k
Steven Μ. Albelda 12913 10474 13327 314 34.7k
Renier J. Brentjens 14711 5037 6602 194 17.7k
Mark E. Dudley 22980 6685 19904 113 28.7k
George Coukos 17255 12693 16776 392 34.6k

All Works

Loading papers...

Rankless by CCL
2026